# A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

> **NCT06564311** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Zenas BioPharma (USA), LLC** · enrollment: 93 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Obexelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06564311
- **Lead sponsor:** Zenas BioPharma (USA), LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2025-08-28
- **Final completion:** 2026-02
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06564311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06564311, "A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06564311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*